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Concurrent malignant melanoma and cutaneous
involvement by classical hodgkin lymphoma
(CHL) in a 63 year-old man
Alejandro A Gru1* and Dongsi Lu2
Abstract
Classical Hodgkin lymphoma (CHL) is a lymphoproliferative disorder that has a bimodal age distribution, affecting
young and elderly individuals, and is curable in more than 90% of patients. Here we report the coexistence of
cutaneous CHL and malignant melanoma as the presentation of papules and a plaque, in an individual with remote
history of systemic CHL. One of the biopsies showed a mononuclear cell infiltrate with Reed-Sternberg (RS) like cells
that were positive for CD30 and CD15, but negative for CD45. A second concurrent biopsy showed an atypical
melanocytic proliferation with significant pagetoid spreading and diffuse Melan-A staining. Based on morphology
alone, it is almost impossible to distinguish CHL from other primary cutaneous lymphoproliferative disorders, such
as CD30+ lymphoproliferative disorder (lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell
lymphoma), or even tumor stage mycosis fungoides when the epidermotropism is minimal. Additionally, bizarre
melanocytic cells can also appear similar to RS cells. Our case illustrates the first case report of malignant melanoma
and CHL in a patient presenting simultaneously.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8979757349937225
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Introduction
Classical Hodgkin lymphoma (CHL) is a lymphoproliferative
disorder that has a bimodal age distribution, affecting young
and elderly individuals, and is curable in more than 90% of
patients. It has a propensity to follow dissemination in a
well-established pattern. This facilitates the use of localized
treatment modalities in its therapeutic approach that include
surgery and radiotherapy. Advanced stage presentations
occur in less than 30% of patients, and the skin is only rarely
affected. Isolated case reports of CHL affecting the skin have
been described. However, CHL can have other cutaneous
manifestations that may not be directly attributed to the
dissemination of the disease. Here we report the coexistence
of CHL and malignant melanoma as the presentation of
papules and a plaque, in an individual with remote history
of CHL. This is the first report of the simultaneous existence
of both disorders.
Case presentation
A 62 year-old man presented with 3–4 months history
of two pink-papules on the scalp, and a pink crusted
plaque on the left neck. He had a previous remote history
of nodular sclerosis classical Hodgkin lymphoma and ther-
apy related acute myeloid leukemia with monosomy 7. His
lymphoma was under control after the chemotherapy, but
he did had bone marrow extension at the time of diagnosis.
A hematopoietic allogeneic transplant was done after his
original diagnosis of acute myeloid leukemia. Two punch
biopsies were obtained. The biopsy from the left neck
(Figure 1) showed a mixed dermal inflammatory infiltrate
with scattered atypical large multinucleated and mono-
nuclear cells, intermixed with aggregates of neutrophils,
small lymphocytes and histiocytes. The mononuclear cells
had hyperchromatic nuclei with vesicular smudged chro-
matin and prominent cherry red nucleoli, resembling
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Reed-Sternberg cells. By immunohistochemistry (Figure 2),
the atypical cells were positive for CD30, CD20, CD79a,
and had dim CD15 and PAX5 staining. They were negative
for CD45. A CD3 and CD43 highlighted the abundant
intermixed T-cells, but were negative among the atypical
large cells. CD68 stained a rich histiocytic background.
A Melan-A and S100 stains were also negative. In-situ
hybridization for EBV was negative as well.
The two biopsies from the scalp (Figure 3) show an
atypical melanocytic proliferation, with features most
compatible with malignant melanoma, largely involving the
dermis. There were large nests of atypical melanocytes with
light eosinophilic cytoplasm, hyperchromatic and vesicular
nuclei with variable prominent nucleoli. Scattered mitotic
figures were seen, including in the deeper portion of
the lesion. No maturation towards the base of the lesion
was seen. An intraepidermal melanocytic component
was present in one of the biopsies. No perineural or
lymphovascular space invasion was identified. Immunohis-
tochemistry for Melan-A and HMB-45 confirmed the
melanocytic origin of the tumor cells.
Discussion
Hodgkin lymphoma (HL) is a disease of young adults
(12% of all lymphomas) and elderly people, and is com-
posed of two separate entities: classical HL (95% of cases)
and nodular lymphocytic predominant HL (5% of cases)
[1]. First described by the German physician Grosz in 1906,
cutaneous Hodgkin lymphoma (CHL), an exceedingly rare
manifestation of the disease (0.5 – 7.5 %), occurs when the
Figure 1 Punch biopsy from the left neck with involvement by HL. 1a and 1b: Hemotoxylin and Eosin stain (20× and 100×). There is an
atypical infiltrate involving the entire dermis with scattered larger cells. A grenz-zone is between the infiltrate and the epidermis. 1c – 1f:
Hemotoxylin and Eosin stain (200× and 400×). The infiltrate is composed predominantly of small lymphocytes and abundant histiocytes in the
background. Several large cells, some of which are binucleated and show prominent nucleoli (compatible with Reed-Sternberg cells and RS variants)
are seen. In addition, scattered neutrophils are also present. Atypical mitoses can be easily detected.
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malignant cells invade the dermis [2]. Nonetheless, cutane-
ous symptoms can be seen in up to 40% of patients with
HL [3]. The current WHO-EORTC classification identifies
cutaneous HL as a secondary systemic dissemination
of the disease [1,4]. Cutaneous manifestation of HL show
different clinical features: (a) papules, (b) plaques, (c)
nodules or tumors, (d) ulcerative lesions, (e) various com-
binations of these features and (f) erythroderma [2]. It is
usually centered in the reticular dermis and commonly
extends into the subcutaneous fat. The tumor shows
nodular or interstitial growth pattern with adnexal in-






Figure 2 Immunohistochemistry of the punch biopsy from the left neck. The atypical cells are positive for CD30, CD79a and CD20. CD15
and PAX5 show positive and dim staining in the tumor cells. CD3 and CD68 (not shown) stain a background of small T-cells and abundant
histiocytes, respectively. The large cells are negative for CD45, EBER and Melan-A (not shown).
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large, hyperchromatic, irregular shaped nuclei are eas-
ily identifiable. The Reed-Sternberg cells are admixed
predominantly with plasma cells and lymphocytes with
occasional histiocytes and eosinophils. Necrosis is gen-
erally absent. The epidermis is spared in most of the
cases [2-5]. In this particular case, the patient had a re-
mote history of nodular sclerosis classical Hodgkin
lymphoma that preceded the secondary involvement of
the skin by many years (10–15 years). Although his ori-
ginal biopsy slides were not available for review, the
histologic features seen on the diagnostic skin biopsy
were more suggestive of a mixed cellularity variant of
CHL: there was an abundance of mixed inflammatory
cells that included neutrophils, histiocytes, plasma cells,
lymphocytes, and rare eosinophils without significant
fibrosis. The population of RS cells and variants was
significant as it is depicted on the Figure 1.
Based on morphology alone, it is almost impossible to
distinguish CHL with abundant numbers of neoplastic
cells from other primary cutaneous lymphoproliferative
disorders, such as CD30+ lymphoproliferative disorder
(lymphomatoid papulosis (LyP) and primary cutaneous
anaplastic large-cell lymphoma (ALCL)), or even tumor
stage mycosis fungoides when the epidermotropism is
minimal. Other reactive CD30+ processes including:
pseudolymphomatous drug reactions, nodular scabies,
atopic dermatitis, and infections can also be in the differ-
ential diagnosis [4].
By immunohistochemistry, the neoplastic cells in




Figure 3 Punch biopsy from the scalp with malignant melanoma. 3a and 3b: Hemotoxylin and Eosin stain (20× and 100×). There is an
atypical melanocytic proliferation with a predominant dermal component, but with individual atypical junctional nests seen. 3c and 3d:
Hemotoxylin and Eosin stain (200× and 400×). The atypical melanocytes are predominantly epithelioid with light eosinophilic cytoplasm,
hyperchromatic and vesicular nuclei with variable prominent nucleoli. Scattered mitotic figures were seen, including in the deeper portion of the
lesion. 3e and 3f: Melan-A immunostain (20× and 100×).
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and CD15 for the majority (75–85%) of cases and are
usually negative for CD45, CD20, ALK and EMA.
However, up to 20-30% of CHL can be positive for
CD20, and its positivity is a marker of better prognosis, and
response to rituximab. The B-cell nature of Reed-Sternberg
cells is shown by the B-cell specific activator protein
(BSAP), product of the PAX-5 gene in approximately
90% of cases. Additionally the tumor cells can be positive
for EBER, by in-situ hybridization [1,5,6]. Other immuno-
histochemical markers that have some utility are OCT-2
and BOB-1, which are positive (not both) in up to 90% of
cases [1]. In contrast, LyP, c-ALCL, or transformed MF
show invariable negative expression of CD15 or Pax-5 [4,6].
A systemic B-cell lymphoma that can sometimes enter in
the differential diagnosis is T-cell histiocyte-rich large B-cell
lymphoma (THRLBCL). But in THCRLBCL there is strong
expression of CD45, CD20, CD79a and PAX-5. The current
case showed a typical CHL immunophenotype with CD30
and CD15 expression, but negative for CD45. An unusual
phenotype with CD20 and CD79a expression was also seen,
but PAX5 showed the classic dim staining characteristic of
CHL. EBER was negative, a feature commonly seen in most
cases of nodular sclerosis and mixed cellularity CHL.
The mode of HL spread to the skin has been explained
by three mechanisms: (1)retrograde lymphatic spread, distal
to the tumor involved regional lymph node(s), which is
the most common; (2)direct extension from an underlying
nodal focus; and (3) hematogenous dissemination where
no tumor-involved lymph nodes are identified in the im-
mediate vicinity of the involved skin [3,4].
The coexistence of different malignancies in patients with
Hodgkin and NHL has been previously documented: Yang
et al. [7] reported a patient with nodal angioimmunoblastic
T-cell lymphoma (AITCL) who had a partial response to
chemotherapy, and developed an EBV-associated cutaneous
diffuse large B-cell lymphoma few months after his original
diagnosis of AITCL. El Demellawy et al. [8] reported a
synchronous collision tumor of malignant melanoma
and chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL). We have also seen in our personal
experience the coexistence of CLL/SLL with melanoma
and squamous cell carcinoma.
Concurrent malignant melanoma and lymphoma occurs
in 0.3% of patients with melanoma [9]. Since 1960, a rising
incidence of melanoma and NHL has been observed,
probably related to UV exposure and immunosupression
(such as cases presenting in individuals who are stem cell
transplant recipients and patients with AIDS) [9,10]. Adami
et al. [10] first reported a link between NHL, CLL/SLL and
skin cancer (the relative risk of developing melanoma was
2.4 among NHL patients) and suggested that UV light may
contribute to increasing incidence of NHL. Riou et al. [11]
reported a 16 fold higher incidence of lymphomas in pa-
tients with malignant melanoma. A recent study also found
a 3.5 to 7.5 fold increase of NHL in patients with melanoma
[9]. Alterations of p16 pathway, which inhibit CDNK4, a
tumor suppressor gene, are common in both types of
malignancies [5,9].
More interestingly, the development of skin cancers
after non-myeloablative allogeneic bone marrow trans-
plants (NMAT) has been well documented. Cavalier
et al. [12] reported a series of 6 cases of skin cancers
(mostly squamous cell carcinomas, but 2 of the patients
had melanoma) in patients with NMAT. The most interest-
ing finding in their study was a particular strong association
of skin cancers in those patients who received their trans-
plant for myelodysplasia or acute myeloid leukemia. In this
case the patient developed a therepy related myeloid
neoplasm subsequent to the chemotherapy for CHL.
The mechanism implicated in the development of skin
cancers is the immunosupression from the induction
chemotherapeutic regimens that are administered
prior to the transplant. In particular, the depletion of
CD4+ lymphocytes is a well known predisposer for skin
cancers. Patients who have an aggressive myeloid neoplasm
usually receive more intensive induction regimens, a
fact that creates a more immunosuppressive background.
Ultimately, fludarabine, a purine analogue that is typically
use in induction chemotherapy, results in DNA inactivation
and apoptosis. Fludarabine also inhibits DNA-polymerase,
RNA-polymerase, DNA-ligase, DNA-primase and ribo-
nucleotide reductase [13]. Fludarabine also depletes CD3,
CD4 and CD8 lymphocytes over a period of a month. In
this case fludarabine was one of the drugs administered
prior to his transplant. Additional possible mechanisms
which are linked to carcinogenesis include p53 mutations
and HPV infection (in squamous cell carcinomas).
In the past, 3 cases of patients with melanoma developed
Hodgkin’s disease thereafter and were published in the lit-
erature [7,9]. However, concurrent cutaneous involvement
by HL and melanoma has never been reported. Causality
between both malignancies remains to be established. Our
case illustrates the first case report of malignant melanoma
and CHL in a patient presenting simultaneously.
Consent
An attempt to obtain informed consent was performed.
However, this patient has been lost to follow up, and no
close family members were available (based on the provided
demographic information) to obtain informed consent from.
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